BriaCell Therapeutics logo

BriaCell TherapeuticsNASDAQ: BCTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

14 March 2012

Next earnings report:

13 December 2024

Last dividends:

N/A

Next dividends:

N/A
$28.57 M
-84%vs. 3y high
28%vs. sector
-vs. 3y high
-vs. sector
-11.99
-134%vs. 3y high
3%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 40 min ago
$0.79+$0.18(+29.25%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

BCTX Latest News

BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns
seekingalpha.com22 October 2024 Sentiment: POSITIVE

BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival. Despite a market cap below $30 million, BriaCell could tap into a $1-$5 billion market upon approval, with valuations between $1-$2 billion. Financing and shareholder dilution remain significant concerns, with recent offerings raising $18.5 million but also massively increasing the share count.

What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock
zacks.com27 September 2024 Sentiment: POSITIVE

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday
benzinga.com11 September 2024 Sentiment: POSITIVE

On Wednesday, BriaCell Therapeutics BCTX stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro.

What type of business is BriaCell Therapeutics?

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

What sector is BriaCell Therapeutics in?

BriaCell Therapeutics is in the Healthcare sector

What industry is BriaCell Therapeutics in?

BriaCell Therapeutics is in the Biotechnology industry

What country is BriaCell Therapeutics from?

BriaCell Therapeutics is headquartered in Canada

When did BriaCell Therapeutics go public?

BriaCell Therapeutics initial public offering (IPO) was on 14 March 2012

What is BriaCell Therapeutics website?

https://briacell.com

Is BriaCell Therapeutics in the S&P 500?

No, BriaCell Therapeutics is not included in the S&P 500 index

Is BriaCell Therapeutics in the NASDAQ 100?

No, BriaCell Therapeutics is not included in the NASDAQ 100 index

Is BriaCell Therapeutics in the Dow Jones?

No, BriaCell Therapeutics is not included in the Dow Jones index

When was BriaCell Therapeutics the previous earnings report?

No data

When does BriaCell Therapeutics earnings report?

The next expected earnings date for BriaCell Therapeutics is 13 December 2024